The kratom industry is facing internal conflict as advocates push for a ban on 7-hydroxymitragynine (7-OH), a potent extract linked to severe withdrawal symptoms and overdoses. This comes after a decade of successful resistance against a DEA ban on kratom itself, raising concerns that negative perceptions of 7-OH could lead to broader regulatory issues for the entire kratom market.
Tensions have escalated with federal officials labeling the 7-OH industry as problematic, while proponents argue for its benefits. The debate highlights the complexities of regulating substances with limited historical use and the potential impact on consumers who rely on kratom products for various reasons.